American Century Companies Inc. Buys 905,960 Shares of IQVIA Holdings Inc. (NYSE:IQV)

American Century Companies Inc. lifted its stake in IQVIA Holdings Inc. (NYSE:IQV) by 396.0% in the 4th quarter, Holdings Channel reports. The institutional investor owned 1,134,737 shares of the medical research company’s stock after acquiring an additional 905,960 shares during the period. American Century Companies Inc.’s holdings in IQVIA were worth $222,987,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Avior Wealth Management LLC lifted its stake in shares of IQVIA by 117.6% in the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after buying an additional 87 shares during the period. Synergy Asset Management LLC acquired a new position in IQVIA in the fourth quarter worth about $33,000. Lee Danner & Bass Inc. acquired a new position in IQVIA in the fourth quarter worth about $44,000. Versant Capital Management Inc raised its position in IQVIA by 46.0% in the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock worth $58,000 after purchasing an additional 93 shares in the last quarter. Finally, SBI Securities Co. Ltd. acquired a new position in IQVIA in the fourth quarter worth about $60,000. Institutional investors own 89.62% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Royal Bank of Canada reissued an “outperform” rating and issued a $270.00 price target on shares of IQVIA in a research report on Monday, February 10th. Citigroup dropped their price target on shares of IQVIA from $225.00 to $210.00 and set a “neutral” rating for the company in a research report on Tuesday, March 4th. Bank of America dropped their price objective on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating for the company in a report on Friday, December 13th. Stephens assumed coverage on shares of IQVIA in a report on Friday, December 20th. They set an “overweight” rating and a $250.00 price objective for the company. Finally, Barclays dropped their price objective on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a report on Monday, February 3rd. Five investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $249.05.

IQVIA Price Performance

Shares of IQV stock opened at $185.85 on Friday. IQVIA Holdings Inc. has a 52-week low of $179.28 and a 52-week high of $254.54. The stock has a market cap of $32.77 billion, a PE ratio of 24.78, a PEG ratio of 1.99 and a beta of 1.50. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The firm’s 50 day moving average price is $194.94 and its two-hundred day moving average price is $208.45.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.